Selentus Science Ltd is pleased to report that its partner CuraMedical BV (the Netherlands) has obtained regulatory approval for TenaTac® in the European Union. TenaTac® is an absorbable haemostat with improved tissue adhesion and is indicated for intra-operative surgical bleeding. The product will be marketed in Europe by CuraMedrix BV (the Netherlands). Dr Ben Nichols, Selentus’ Chairman, commented that TenaTac has great potential in the European market and they anticipate further partnerships in North America and Asia-Pacific.
For further information please contact Ben Nichols +44 (0)7 565 825 662 or [email protected]
In Asia-Pacific please contact Ben Walker (+852) 6200 8250 or [email protected]
